Curis Achieves Milestone under Wyeth Collaboration.

CAMBRIDGE, Mass. -- Curis, Inc. (NASDAQ: CRIS), a therapeutic drug development company, today announced that it has achieved a development milestone under a collaboration with one of its corporate partners, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE). The milestone is based on Wyeth's and Curis' continued progress in preclinical development of Hedgehog pathway agonists for the treatment of stroke, neurological and other disorders. The milestone will trigger a modest payment from Wyeth to Curis in accordance with the terms of their 2004 agreement.

The Hedgehog signaling pathway regulates the normal development of the brain and spinal cord. Wyeth and Curis are collaborating to develop several promising small molecule agonist compounds that can activate the Hedgehog signaling pathway and thereby promote nervous system repair. Many of these small molecules are orally available and can enter into the brain and spinal cord, thus making them an attractive new class of drug development candidates for neurological disorders.

Daniel Passeri, President and Chief Executive Officer of Curis, said, "We are very pleased with the progress that has been made with Wyeth in the Hedgehog agonist program. The achievement of this milestone is an important next step in the path of bringing these promising drug candidates towards clinical trials and ultimately to the patients who need them."

About the Wyeth Curis Collaboration

In January 2004, Curis licensed its Hedgehog proteins and novel small molecule Hedgehog pathway agonists to Wyeth for therapeutic applications in the treatment of neurological and other disorders. Under the terms of the agreement, Wyeth has paid Curis a license fee, has been providing financial support for a minimum of two years of Curis research dedicated to the program, and will make additional cash payments to Curis upon the successful achievement of development, clinical, and drug approval milestones. Wyeth will also pay a royalty on net product sales that escalates with increasing sales volume.

As part of the agreement, Curis has retained development and licensing options for certain therapeutic applications of the Hedgehog agonist technologies, including topical applications for hair growth and local delivery applications for treatment of cardiovascular disease.

About Curis, Inc.

Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer (under partnership with Genentech, which also includes a co-development collaboration between Curis and Genentech for a basal cell carcinoma product candidate), kidney disease (licensed to Ortho Biotech, a subsidiary of Johnson & Johnson), neurological disorders (partnered with Wyeth Pharmaceuticals), hair growth, and cardiovascular disease. For more information, please visit the Curis web site at www.curis.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Curis' drug discovery and development programs. Such statements may contain the words "believes", "expects", "anticipates", "plans", "seeks", "estimates" or similar expressions. These forward looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other factors that may cause Curis' actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by a number of important factors including, among other things: adverse results in Curis' and its strategic partners' product development programs; difficulties or delays in obtaining or maintaining required regulatory approvals; Curis' ability to obtain or maintain the patent and other proprietary intellectual property protection necessary for the development and commercialization of products based on its technologies; changes in or Curis' inability to execute its realigned business strategy; the risk that Curis does not obtain the additional funding required to conduct research and development of its product candidates and execute on its business plan; unplanned cash requirements and expenditures; risks relating to Curis' ability to enter into and maintain important strategic partnerships, including its ability to maintain its current collaboration agreements with Genentech, Ortho and Wyeth; the risk that competitors will discover and develop signaling pathway-based therapeutics faster and more successfully that Curis and its collaborators are able to; and other risk factors identified in Curis' most recent Annual Report on Form 10-K, Quarterly Report on 10-Q and any subsequent reports filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise.